|MDACC Study No:||2010-0323 (clinicaltrials.gov NCT No: NCT01083602)|
|Title:||A phase II, multi-center, single arm, open label study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma|
|Principal Investigator:||Donna M. Weber|
|Treatment Agent:||Bortezomib; Dexamethasone; LBH589|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
panobinostat, bortezomib, and dexamethasone can help to control MM. The safety
of these drugs will also be studied.